(Q39156112)

9 September 2017

miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. (English)

1 reference

9 September 2017

0 references

Jie Wang

1

1 reference

9 September 2017

Ke Sai

series ordinal

2

1 reference

9 September 2017

Fu-rong Chen

series ordinal

3

1 reference

9 September 2017

Zhong-ping Chen

series ordinal

4

1 reference

9 September 2017

5 May 2013

1 reference

Cancer Chemotherapy and Pharmacology

9 September 2017

1 reference

9 September 2017

72

1 reference

9 September 2017

1

1 reference

9 September 2017

147-158

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2180-3

9 September 2017

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNAs: genomics, biogenesis, mechanism, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Role of microRNAs in drug-resistant ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Polyploidy in atypical grade II choroid plexus papilloma of the posterior fossa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNAs as potential cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Tumour cell survival signalling by the ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2180-3

10.1007/S00280-013-2180-3

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference